Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 Days Inventory is 106.17 as of Mar. 2026, which is 9% below its 10-year median of 117.29. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.67 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Perseus Proteomics ranks better than 56.88% on this metric.
The historical rank and industry rank for Perseus Proteomics's Days Inventory or its related term are showing as below:
TSE:4882'
s Days Inventory Range Over the Past 10 Years
Min: 5.91 Med: 117.29 Max: 226.85
Current: 148.97
During the past 9 years, Perseus Proteomics's highest Days Inventory was 226.85. The lowest was 5.91. And the median was 117.29.
TSE:4882's Days Inventory is ranked better than 56.88% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs TSE:4882: 148.97
Perseus Proteomics's Days Inventory
increased
from Mar. 2025 (82.55) to Mar. 2026 (106.17).
It might indicate that Perseus Proteomics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Perseus Proteomics's Inventory Turnover for the
six
months ended in Mar. 2026 was 1.72.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Perseus Proteomics's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.12.
Perseus Proteomics (TSE:4882) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Perseus Proteomics's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Perseus Proteomics's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Perseus Proteomics Days Inventory Related Terms
Perseus Proteomics Days Inventory Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a Days Inventory of 106.17 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Perseus Proteomics and its competitors. This is near median its historical median of 117.29. Over the past decade, Perseus Proteomics' Days Inventory has ranged from 5.91 to 226.85. According to the industry distribution chart, Perseus Proteomics ranks #398 out of 923 companies in the Drug Manufacturers industry, placing it in the top 43.1%.
Is Perseus Proteomics' Days Inventory too high?
Perseus Proteomics' current Days Inventory of 106.17 is near median its 10-year median of 117.29. Over the past 10 years, this metric has ranged from a low of 5.91 to a high of 226.85. The Drug Manufacturers industry median Days Inventory is 164.38. Perseus Proteomics' value of 106.17 is 35.4% below this industry median. Based on the distribution chart, Perseus Proteomics ranks #398 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #398 out of 923 companies for Days Inventory. This puts Perseus Proteomics in the upper half of its industry. The industry median Days Inventory is 164.38. Perseus Proteomics' value of 106.17 is 35.4% below this benchmark. Historically, Perseus Proteomics' own Days Inventory has ranged from 5.91 to 226.85 over the past decade. While the company's 10-year median is 117.29 vs. the industry median of 164.38, Perseus Proteomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current Days Inventory of 106.17 is 35.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Days Inventory is 106.17, which is near median its own 10-year median of 117.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.67, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Days Inventory is 106.17, which is near median its 10-year median of 117.29 and 35.4% below the Drug Manufacturers industry median of 164.38. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Days Inventory is 106.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.67.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Days Inventory: 106.17 (near median its 10-year median of 117.29)
GF Value™: 円439.67 vs. price of 円160.00 (63.6% below fair value)
Industry Position: 35.4% below the Drug Manufacturers median (#398 of 923)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
